Search results
MambaOut: Do We Really Need Mamba for Vision?
Unite.ai· 1 day agoAlthough including transformers in the model architecture gives a significant boost in the model performance, the attention module in Transformers scales with the sequence length quadratically ...
Ignored Failures Of A High-Volume Joint Replacement Society
Forbes· 6 days agoThere’s just not enough time – or enough incentive – to convey and process the gravity of undergoing...
Vedanta Biosciences doses first subject in Phase III C difficile prevention trial
Clinical Trials Arena via Yahoo Finance· 4 days ago“Based on the efficacy and safety data we have generated to date for this programme, we believe that...
Eating disorders: Can nutritional deficiencies be overcome with high doses of food supplements?
Nutraingredients.com· 6 days agoAn eating disorder may present from many factors, including biological, genetic, environmental, social, psychological and psychiatric ones. Among the most common ED-related conditions are anorexia ...
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at...
Benzinga· 5 days agoDupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM NOTUS results confirm landmark data from the phase 3 BOREAS study and show Dupixent significantly
Induced dual-target rebalance simultaneously enhances efficient therapeutical efficacy in tumors -...
Nature· 3 days agoMultiple gene abnormalities are major drivers of tumorigenesis. NF-κB p65 overactivation and cGAS silencing are important triggers and genetic defects that accelerate tumorigenesis. However, ...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 5 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 as Monotherapy or Combined with...
Morningstar· 6 days agoPRINCETON, NJ / ACCESSWIRE / May 20, 2024 / Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the "Company" or "Sonnet"), a clinical-stage company developing targeted immunotherapeutic drugs ...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 2 days agoHOOKIPA to present an oral abstract at the American Society for Clinical Oncology (ASCO) 2024 Annual Meeting on June 4Updated data of HB-200 plus pembrolizumab demonstrate a favorable safety profile and promising clinical activity In a subset
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 3 days agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...
